Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2019-07-22 Net Asset Value
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Net Asset Value Classification · 95% confidence The document is titled "Bilan semestriel du Contrat de Liquidité contracté avec CM-CIC Securities" (Semi-annual balance sheet of the Liquidity Contract with CM-CIC Securities). It details the status of the liquidity contract (share count and cash balance) as of June 30, 2019, and transaction volumes (purchases and sales) during the first semester of 2019. This type of announcement, which reports on specific financial arrangements or capital management activities (like liquidity contracts or share buybacks), aligns best with the 'Transaction in Own Shares' (POS) category, as liquidity contracts are mechanisms for managing share price stability, often involving share transactions. Although it is a semi-annual report on a specific contract, it is not a comprehensive financial report (10-K or IR). Given the focus on share transactions under a liquidity agreement, POS is the most appropriate fit over other capital/financing codes like CAP.
2019-07-22 French
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to a declaration of crossing shareholding thresholds according to French commercial code. It explicitly states that the shareholder Winance crossed down the thresholds of 25%, 20%, 15%, and 10% of the capital and voting rights of GENOMIC VISION, now holding 8.13%. This type of filing, reporting changes in significant share ownership levels, directly corresponds to the Major Shareholding Notification category.
2019-07-19 French
Informations privilégiées / Autres communiqués
AGM Information Classification · 99% confidence The document is explicitly titled "Genomic Vision : compte rendu de l'Assemblée Générale Mixte du 8 juillet 2019" (Genomic Vision: minutes/report of the Combined General Meeting of July 8, 2019). It discusses the resolutions passed (or not passed) during the Ordinary General Meeting (AGO) and notes that the Extraordinary General Meeting (AGE) resolutions could not be deliberated upon due to lack of quorum. This content directly relates to the proceedings and outcomes of the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length (4857 chars) is substantial enough to be the report itself, not just a brief announcement of publication.
2019-07-09 French
Inside Information / Other news releases
AGM Information Classification · 99% confidence The document explicitly states in the title and body that it is the "report of the Combined Shareholders' Meeting of July 8, 2019". It details the resolutions passed and notes that the quorum was not met for the extraordinary resolutions. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document length (4503 chars) is substantial enough to be the report itself, not just a brief announcement of publication.
2019-07-09 English
Inside Information / Other news releases
Capital/Financing Update Classification · 98% confidence The document is an announcement titled "Genomic Vision announces the acceptance notice of the second tranche of €1.0 million within the framework of the equity financing put in place with Winance." It explicitly details the issuance of 10,000,000 new shares corresponding to a capital increase of €1.0 million, which is a form of financing activity. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it mentions a prospectus filed with the AMF, the primary purpose of this text is to announce the execution of a financing tranche, not to be the prospectus itself or a general regulatory filing.
2019-07-04 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document announces that Genomic Vision has initiated the issuance of 10,000,000 new shares corresponding to a capital increase of €1.0 M under a financing agreement with Winance. This action directly relates to fundraising, financing activities, and capital structure changes (issuance of new shares/capital increase). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves issuing shares (which could relate to SHA), the context is specifically about drawing down a tranche of a pre-arranged financing facility, making CAP the most precise classification.
2019-07-04 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.